On the public citation graph

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

https://doi.org/10.1016/j.it.2019.04.002

0 signed · 372 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2015.4368openalex-snapshot

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

inferredcites →https://doi.org/10.1001/jamaoncol.2017.2391openalex-snapshot

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

inferredcites →https://doi.org/10.1001/jamaoncol.2018.3923openalex-snapshot

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

inferredcites →https://doi.org/10.1016/j.cell.2015.03.030openalex-snapshot

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

inferredcites →https://doi.org/10.1016/j.cell.2015.08.052openalex-snapshot

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

inferredcites →https://doi.org/10.1016/j.cell.2017.07.024openalex-snapshot

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

inferredcites →https://doi.org/10.1016/j.cell.2017.09.028openalex-snapshot

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

inferredcites →https://doi.org/10.1016/j.cell.2018.10.038openalex-snapshot

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

inferredcites →https://doi.org/10.1016/j.celrep.2014.03.004openalex-snapshot

GILZ Promotes Production of Peripherally Induced Treg Cells and Mediates the Crosstalk between Glucocorticoids and TGF-β Signaling

inferredcites →https://doi.org/10.1016/j.immuni.2016.05.002openalex-snapshot

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

inferredcites →https://doi.org/10.1016/j.immuni.2018.05.006openalex-snapshot

PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells

inferredcites →https://doi.org/10.1016/j.immuni.2018.11.014openalex-snapshot

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

inferredcites →https://doi.org/10.1016/j.immuni.2018.12.021openalex-snapshot

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

inferredcites →https://doi.org/10.1016/j.it.2015.02.008openalex-snapshot

Overcoming T cell exhaustion in infection and cancer

inferredcites →https://doi.org/10.1016/s1470-2045(16)30126-7openalex-snapshot

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

inferredcites →https://doi.org/10.1016/s1470-2045(16)30366-7openalex-snapshot

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

inferredcites →https://doi.org/10.1016/s1470-2045(17)30428-xopenalex-snapshot

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

inferredcites →https://doi.org/10.1016/s1470-2045(18)30700-9openalex-snapshot

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

inferredcites →https://doi.org/10.1021/acs.chemrev.9b00738openalex-snapshot

ImmunoPET: Concept, Design, and Applications

inferredcites →https://doi.org/10.1021/acscentsci.9b01065openalex-snapshot

Computational Design of an Allosteric Antibody Switch by Deletion and Rescue of a Complex Structural Constellation

inferredcites →https://doi.org/10.1038/mt.2010.24openalex-snapshot

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

inferredcites →https://doi.org/10.1038/nature03723openalex-snapshot

Paths to understanding the genetic basis of autoimmune disease

inferredcites →https://doi.org/10.1038/nature04444openalex-snapshot

Restoring function in exhausted CD8 T cells during chronic viral infection

inferredcites →https://doi.org/10.1038/nature13954openalex-snapshot

PD-1 blockade induces responses by inhibiting adaptive immune resistance

inferredcites →https://doi.org/10.1038/nature14011openalex-snapshot

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

inferredcites →https://doi.org/10.1038/nature14292openalex-snapshot

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

inferredcites →https://doi.org/10.1038/nature21349openalex-snapshot

Elements of cancer immunity and the cancer–immune set point

inferredcites →https://doi.org/10.1038/nature22079openalex-snapshot

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

inferredcites →https://doi.org/10.1038/ni.2496openalex-snapshot

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood

inferredcites →https://doi.org/10.1038/nrc3239openalex-snapshot

The blockade of immune checkpoints in cancer immunotherapy

inferredcites →https://doi.org/10.1038/nrclinonc.2016.58openalex-snapshot

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

inferredcites →https://doi.org/10.1038/nrclinonc.2017.88openalex-snapshot

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

inferredcites →https://doi.org/10.1038/nri.2017.108openalex-snapshot

The diverse functions of the PD1 inhibitory pathway

inferredcites →https://doi.org/10.1038/nri3442openalex-snapshot

The integration of T cell migration, differentiation and function

inferredcites →https://doi.org/10.1038/s41590-019-0312-6openalex-snapshot

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

inferredcites →https://doi.org/10.1038/s41591-018-0057-zopenalex-snapshot

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-snapshot

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1103849openalex-snapshot

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

inferredcites →https://doi.org/10.1056/nejmoa1200690openalex-snapshot

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

inferredcites →https://doi.org/10.1056/nejmoa1407222openalex-snapshot

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

inferredcites →https://doi.org/10.1056/nejmoa1500596openalex-snapshot

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

inferredcites →https://doi.org/10.1056/nejmoa1501824openalex-snapshot

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1503093openalex-snapshot

Pembrolizumab versus Ipilimumab in Advanced Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1611299openalex-snapshot

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

inferredcites →https://doi.org/10.1056/nejmoa1709684openalex-snapshot

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

inferredcites →https://doi.org/10.1056/nejmoa1807315openalex-snapshot

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

inferredcites →https://doi.org/10.1056/nejmra1703481openalex-snapshot

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

inferredcites →https://doi.org/10.1073/pnas.1604268113openalex-snapshot

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

inferredcites →https://doi.org/10.1073/pnas.96.20.11476openalex-snapshot

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance

inferredcites →https://doi.org/10.1080/2162402x.2018.1466016openalex-snapshot

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

inferredcites →https://doi.org/10.1084/jem.182.2.459openalex-snapshot

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

inferredcites →https://doi.org/10.1084/jem.20090847openalex-snapshot

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

inferredcites →https://doi.org/10.1084/jem.20141030openalex-snapshot

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

inferredcites →https://doi.org/10.1093/annonc/mdw443openalex-snapshot

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

inferredcites →https://doi.org/10.1093/annonc/mdx225openalex-snapshot

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

inferredcites →https://doi.org/10.1097/cji.0b013e3182829903openalex-snapshot

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

inferredcites →https://doi.org/10.1111/imr.12411openalex-snapshot

T follicular regulatory cells

inferredcites →https://doi.org/10.1126/science.1160062openalex-snapshot

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

inferredcites →https://doi.org/10.1126/science.aaa8172openalex-snapshot

The future of immune checkpoint therapy

inferredcites →https://doi.org/10.1126/science.aar4060openalex-snapshot

Cancer immunotherapy using checkpoint blockade

inferredcites →https://doi.org/10.1126/science.aar6711openalex-snapshot

CAR T cell immunotherapy for human cancer

inferredcites →https://doi.org/10.1126/scitranslmed.3003130openalex-snapshot

The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T Cells

inferredcites →https://doi.org/10.1126/scitranslmed.3003689openalex-snapshot

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

inferredcites →https://doi.org/10.1126/scitranslmed.3005930openalex-snapshot

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

inferredcites →https://doi.org/10.1126/scitranslmed.3006034openalex-snapshot

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

inferredcites →https://doi.org/10.1126/scitranslmed.3008918openalex-snapshot

Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response

inferredcites →https://doi.org/10.1136/jitc-2019-000451openalex-snapshot

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

inferredcites →https://doi.org/10.1136/jitc-2020-000958openalex-snapshot

Immune checkpoint inhibitor-associated celiac disease

inferredcites →https://doi.org/10.1158/0008-5472.can-16-3431openalex-snapshot

Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells

inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-2564openalex-snapshot

Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma

inferredcites →https://doi.org/10.1158/2159-8290.cd-14-0863openalex-snapshot

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

inferredcites →https://doi.org/10.1158/2159-8290.cd-16-0040openalex-snapshot

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

inferredcites →https://doi.org/10.1158/2159-8290.cd-17-1319openalex-snapshot

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

inferredcites →https://doi.org/10.1159/000453569openalex-snapshot

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

inferredcites →https://doi.org/10.1159/000455014openalex-snapshot

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

inferredcites →https://doi.org/10.1172/jci.insight.89140openalex-snapshot

Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy

inferredcites →https://doi.org/10.1172/jci123391openalex-snapshot

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

inferredcites →https://doi.org/10.1172/jci62860openalex-snapshot

Viral acute lower respiratory infections impair CD8+ T cells through PD-1

inferredcites →https://doi.org/10.1172/jci87324openalex-snapshot

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

inferredcites →https://doi.org/10.1182/blood-2016-04-712612openalex-snapshot

CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency

inferredcites →https://doi.org/10.1186/s40425-017-0300-zopenalex-snapshot

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

inferredcites →https://doi.org/10.1186/s40425-018-0461-4openalex-snapshot

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

inferredcites →https://doi.org/10.1200/jco.2009.26.7609openalex-snapshot

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

inferredcites →https://doi.org/10.1200/jco.2012.41.6750openalex-snapshot

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

inferredcites →https://doi.org/10.1200/jco.2016.72.1985openalex-snapshot

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

inferredcites →https://doi.org/10.1200/jco.2017.77.6385openalex-snapshot

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

inferredcites →https://doi.org/10.1200/jco.2018.79.0006openalex-snapshot

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.18632/oncotarget.25627openalex-snapshot

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients

inferredcites →https://doi.org/10.21037/hbsn.2019.10.25openalex-snapshot

Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies

inferredcites →https://doi.org/10.2337/dbi18-0002openalex-snapshot

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

inferredcites →https://doi.org/10.3389/fimmu.2017.01547openalex-snapshot

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract

inferredcites →https://doi.org/10.3389/fonc.2019.00052openalex-snapshot

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors

inferredcites →https://doi.org/10.4049/jimmunol.1401686openalex-snapshot

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

inferredcites →https://doi.org/10.4049/jimmunol.170.9.4833openalex-snapshot

Inhibition of IFN-γ Signaling by Glucocorticoids

inferredcites →https://doi.org/10.4161/onci.29244openalex-snapshot

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4652904openalex-extracted

A Dual-Functional Oncolytic Adenovirus Armed with Pd-L1 Inhibitor Potentiates its Antitumor Activity

inferred← citeshttps://doi.org/10.1002/14651858.cd014907openalex-snapshot

Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

inferred← citeshttps://doi.org/10.1002/14651858.cd014907.pub2openalex-snapshot

Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

inferred← citeshttps://doi.org/10.1002/14651858.cd015495openalex-snapshot

Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/14651858.cd016104openalex-snapshot

Perioperative immune checkpoint inhibitors with or without chemotherapy versus placebo with or without chemotherapy in elderly people with localised non-small cell lung cancer

inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm135.pub2openalex-snapshot

Gastrointestinal and Hepatic Complications in Cancer Patients

inferred← citeshttps://doi.org/10.1002/adfm.201906922openalex-snapshot

In Situ Formed Fibrin Scaffold with Cyclophosphamide to Synergize with Immune Checkpoint Blockade for Inhibition of Cancer Recurrence after Surgery

inferred← citeshttps://doi.org/10.1002/adfm.202100386openalex-snapshot

Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer

inferred← citeshttps://doi.org/10.1002/cac2.12539openalex-snapshot

Immunologic tumor microenvironment modulators for turning cold tumors hot

inferred← citeshttps://doi.org/10.1002/cac2.12587openalex-snapshot

Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies

inferred← citeshttps://doi.org/10.1002/cam4.2397openalex-snapshot

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control

inferred← citeshttps://doi.org/10.1002/cam4.70011openalex-snapshot

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1002/cam4.7188openalex-snapshot

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1002/cncr.32966openalex-snapshot

Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis

inferred← citeshttps://doi.org/10.1002/cncr.70262openalex-snapshot

Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele

inferred← citeshttps://doi.org/10.1002/cnr2.70274openalex-snapshot

Immune Checkpoint Inhibitor‐Related Dysautonomia in Merkel Cell Carcinoma: A Case Report

inferred← citeshttps://doi.org/10.1002/ctm2.1613openalex-snapshot

Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies

inferred← citeshttps://doi.org/10.1002/exp.20220173openalex-snapshot

Gel/hydrogel‐based in situ biomaterial platforms for cancer postoperative treatment and recovery

inferred← citeshttps://doi.org/10.1002/ijc.33813openalex-snapshot

Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma

inferred← citeshttps://doi.org/10.1002/mco2.70176openalex-snapshot

Application of Immune Checkpoint Inhibitors in Cancer

inferred← citeshttps://doi.org/10.1002/mdr2.70019openalex-snapshot

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

inferred← citeshttps://doi.org/10.1002/smll.202004905openalex-snapshot

Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy

inferred← citeshttps://doi.org/10.1007/978-981-15-3266-5_7openalex-snapshot

Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy

inferred← citeshttps://doi.org/10.1007/s00011-026-02211-yopenalex-snapshot

Immune checkpoint molecules beyond PD-1 and CTLA-4: emerging targets in autoimmune diseases and cancer immunotherapy

inferred← citeshttps://doi.org/10.1007/s00228-024-03647-zopenalex-snapshot

Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis

inferred← citeshttps://doi.org/10.1007/s00228-025-03960-1openalex-snapshot

Safety of immune checkpoint inhibitors: A systematic review of disproportionality analysis studies

inferred← citeshttps://doi.org/10.1007/s00262-023-03428-0openalex-snapshot

Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC

inferred← citeshttps://doi.org/10.1007/s00330-021-07925-7openalex-snapshot

Multi-detector computed tomography (MDCT)–based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis

inferred← citeshttps://doi.org/10.1007/s00432-023-05364-zopenalex-snapshot

Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma

inferred← citeshttps://doi.org/10.1007/s00432-024-05703-8openalex-snapshot

Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world

inferred← citeshttps://doi.org/10.1007/s00520-020-05707-3openalex-snapshot

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors

inferred← citeshttps://doi.org/10.1007/s10620-022-07598-2openalex-snapshot

CD8+ Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors

inferred← citeshttps://doi.org/10.1007/s11033-024-09418-4openalex-snapshot

STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity

inferred← citeshttps://doi.org/10.1007/s11892-021-01384-6openalex-snapshot

The Role of Programmed Death-1 in Type 1 Diabetes

inferred← citeshttps://doi.org/10.1007/s11894-020-0752-zopenalex-snapshot

Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives

inferred← citeshttps://doi.org/10.1007/s11894-022-00852-7openalex-snapshot

Update on Immune Checkpoint Inhibitor Enterocolitis

inferred← citeshttps://doi.org/10.1007/s11926-021-00991-2openalex-snapshot

Checkpoint Molecules in Rheumatology—or the Benefits of Being Exhausted

inferred← citeshttps://doi.org/10.1007/s12012-026-10131-wopenalex-snapshot

Immune Checkpoint Inhibitor–Associated Cardiovascular Toxicity: Mechanisms, Clinical Manifestations, and Clinical Impact

inferred← citeshttps://doi.org/10.1007/s43188-024-00233-4openalex-snapshot

Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer

inferred← citeshttps://doi.org/10.1016/b978-0-12-823397-9.00015-6openalex-snapshot

Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies

inferred← citeshttps://doi.org/10.1016/b978-0-443-18770-4.00007-xopenalex-snapshot

Inhaled delivery of immunotherapy for treatment of lung cancer

inferred← citeshttps://doi.org/10.1016/j.abb.2022.109165openalex-snapshot

Biocatalysis of precursors to new-generation SB-T-taxanes effective against paclitaxel-resistant cancer cells

inferred← citeshttps://doi.org/10.1016/j.addr.2022.114317openalex-snapshot

Demystifying phytoconstituent-derived nanomedicines in their immunoregulatory and therapeutic roles in inflammatory diseases

inferred← citeshttps://doi.org/10.1016/j.apsb.2020.12.018openalex-snapshot

Biological drug and drug delivery-mediated immunotherapy

inferred← citeshttps://doi.org/10.1016/j.bbcan.2026.189544openalex-snapshot

Immunotherapy-driven remodeling of the tumor immune microenvironment: Spatiotemporal heterogeneity and multidimensional dynamics

inferred← citeshttps://doi.org/10.1016/j.bbih.2023.100720openalex-snapshot

Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series

inferred← citeshttps://doi.org/10.1016/j.biomaterials.2020.120200openalex-snapshot

Emerging nanotherapeutics for antithrombotic treatment

inferred← citeshttps://doi.org/10.1016/j.biomaterials.2022.121433openalex-snapshot

Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy

inferred← citeshttps://doi.org/10.1016/j.cej.2022.136428openalex-snapshot

Improved Immunotherapy for Gastric Cancer by Nanocomposites with Capability of Triggering Dual-Damage of Nuclear/Mitochondrial DNA and Cgas/Sting-Mediated Innate Immunity

inferred← citeshttps://doi.org/10.1016/j.cell.2021.02.011openalex-snapshot

Understanding and treating the inflammatory adverse events of cancer immunotherapy

inferred← citeshttps://doi.org/10.1016/j.cell.2021.09.020openalex-snapshot

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

inferred← citeshttps://doi.org/10.1016/j.celrep.2019.11.056openalex-snapshot

Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas Through the PD-1/PD-L1 Pathway

inferred← citeshttps://doi.org/10.1016/j.celrep.2023.112219openalex-snapshot

IFNγ is a central node of cancer immune equilibrium

inferred← citeshttps://doi.org/10.1016/j.chembiol.2019.12.007openalex-snapshot

Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy

inferred← citeshttps://doi.org/10.1016/j.chom.2026.03.008openalex-snapshot

The skin microbiota drives cutaneous immune checkpoint inhibitor toxicity in genetically susceptible mice

inferred← citeshttps://doi.org/10.1016/j.cll.2019.07.012openalex-snapshot

Testing Immune-Related Adverse Events in Cancer Immunotherapy

inferred← citeshttps://doi.org/10.1016/j.clnesp.2021.12.024openalex-snapshot

A historic cohort study of nutritional status related side effects and weight loss of cancer patients treated with immunotherapy

inferred← citeshttps://doi.org/10.1016/j.coi.2020.06.001openalex-snapshot

Inhibitory receptor agonists: the future of autoimmune disease therapeutics?

inferred← citeshttps://doi.org/10.1016/j.coi.2023.102283openalex-snapshot

Immune checkpoint receptors in autoimmunity

inferred← citeshttps://doi.org/10.1016/j.cotox.2020.03.002openalex-snapshot

Transforming preclinical assessment to meet clinical relevance with advanced models

inferred← citeshttps://doi.org/10.1016/j.cpccr.2025.100387openalex-snapshot

Immune checkpoint inhibitor esophagitis with excellent response to oral viscous budesonide

inferred← citeshttps://doi.org/10.1016/j.critrevonc.2025.104808openalex-snapshot

T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejca.2020.09.032openalex-snapshot

How to manage patients with corticosteroids in oncology in the era of immunotherapy?

inferred← citeshttps://doi.org/10.1016/j.gie.2024.01.024openalex-snapshot

Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients

inferred← citeshttps://doi.org/10.1016/j.gtc.2021.12.006openalex-snapshot

Mimics of Crohn's Disease

inferred← citeshttps://doi.org/10.1016/j.humpath.2022.06.014openalex-snapshot

Drug-induced digestive tract injury: decoding some invisible offenders

inferred← citeshttps://doi.org/10.1016/j.ijpharm.2026.126929openalex-snapshot

Mesenchymal stem cell-derived exosome-inspired nanoformulations: a new frontier in targeted cancer therapy

inferred← citeshttps://doi.org/10.1016/j.intimp.2022.109300openalex-snapshot

Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles

inferred← citeshttps://doi.org/10.1016/j.intimp.2024.111579openalex-snapshot

A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity

inferred← citeshttps://doi.org/10.1016/j.isci.2020.101458openalex-snapshot

Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy

inferred← citeshttps://doi.org/10.1016/j.isci.2020.101580openalex-snapshot

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade

inferred← citeshttps://doi.org/10.1016/j.it.2019.10.006openalex-snapshot

Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1

inferred← citeshttps://doi.org/10.1016/j.jaut.2024.103339openalex-snapshot

PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation – therapeutic implications for autoimmunity

inferred← citeshttps://doi.org/10.1016/j.jfutfo.2026.09.025openalex-snapshot

Food and Medicine Homology Substances Remodel Gut Microbiota for Tumor Therapy

inferred← citeshttps://doi.org/10.1016/j.jtocrr.2020.100074openalex-snapshot

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

inferred← citeshttps://doi.org/10.1016/j.lfs.2020.118110openalex-snapshot

Immune escape: A critical hallmark in solid tumors

inferred← citeshttps://doi.org/10.1016/j.medin.2026.502518openalex-snapshot

Inmunoterapia en el paciente crítico con cáncer: lo que el intensivista debe conocer

inferred← citeshttps://doi.org/10.1016/j.medine.2026.502518openalex-snapshot

Immunotherapy in the critically ill cancer patient: What the intensivist should know

inferred← citeshttps://doi.org/10.1016/j.path.2023.05.007openalex-snapshot

Histopathologic Manifestations of Immune Checkpoint Inhibitor Therapy-Associated Gastrointestinal Tract Injury

inferred← citeshttps://doi.org/10.1016/j.phrs.2024.107489openalex-snapshot

A theranostic photosensitizer-conjugated albumin co-loading with resiquimod for cancer-targeted imaging and robust photo-immunotherapy

inferred← citeshttps://doi.org/10.1016/j.plrev.2021.10.001openalex-snapshot

Improving cancer treatments via dynamical biophysical models

inferred← citeshttps://doi.org/10.1016/j.semcancer.2025.09.006openalex-snapshot

Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments

inferred← citeshttps://doi.org/10.1016/j.tranon.2021.101337openalex-snapshot

Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice

inferred← citeshttps://doi.org/10.1016/j.trecan.2022.02.008openalex-snapshot

Elevated circulating memory T cells precede immunotherapy toxicities in melanoma

inferred← citeshttps://doi.org/10.1016/j.trecan.2023.04.002openalex-snapshot

Immune mechanisms of toxicity from checkpoint inhibitors

inferred← citeshttps://doi.org/10.1016/j.xjidi.2026.100450openalex-snapshot

Association of immune checkpoint inhibitor-induced bullous pemphigoid with underlying cancer type: A lack of association with cancer tissue COL17A1 mutations and dysregulation

inferred← citeshttps://doi.org/10.1016/j.ymthe.2022.06.013openalex-snapshot

Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes

inferred← citeshttps://doi.org/10.1016/s0016-5085(22)60201-4openalex-snapshot

375: CONCURRENT IMMUNE CHECKPOINT INHIBITION AND SELECTIVE IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH IMMUNE-RELATED ENTEROCOLITIS

inferred← citeshttps://doi.org/10.1021/acs.chemrev.9b00738openalex-snapshot

ImmunoPET: Concept, Design, and Applications

inferred← citeshttps://doi.org/10.1021/acsami.1c16636openalex-snapshot

Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy

inferred← citeshttps://doi.org/10.1021/acsami.9b17137openalex-snapshot

Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment

inferred← citeshttps://doi.org/10.1021/acscentsci.9b01065openalex-snapshot

Computational Design of an Allosteric Antibody Switch by Deletion and Rescue of a Complex Structural Constellation

inferred← citeshttps://doi.org/10.1021/acsnano.1c02391openalex-snapshot

Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver

inferred← citeshttps://doi.org/10.1021/mc-2023-vol58.ch10openalex-snapshot

SMALL-MOLECULE DEGRADERS OF IKAROS ZINC FINGER (IKZF) TRANSCRIPTION FACTORS

inferred← citeshttps://doi.org/10.1038/d41586-021-00421-4openalex-snapshot

Cancer aided by greasy traitors

inferred← citeshttps://doi.org/10.1038/s41379-020-00653-1openalex-snapshot

Liver biopsy findings in patients on immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1038/s41392-023-01522-4openalex-snapshot

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

inferred← citeshttps://doi.org/10.1038/s41401-025-01652-1openalex-snapshot

An engineered IL-21 variant is a potent antitumor candidate for antitumor immunotherapy

inferred← citeshttps://doi.org/10.1038/s41416-022-02073-1openalex-snapshot

Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer

inferred← citeshttps://doi.org/10.1038/s41422-020-00395-4openalex-snapshot

Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy

inferred← citeshttps://doi.org/10.1038/s41467-021-22885-8openalex-snapshot

Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas

inferred← citeshttps://doi.org/10.1038/s41467-023-44512-4openalex-snapshot

Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis

inferred← citeshttps://doi.org/10.1038/s41467-025-57124-xopenalex-snapshot

S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity

inferred← citeshttps://doi.org/10.1038/s41572-020-0160-6openalex-snapshot

Immune-related adverse events of checkpoint inhibitors

inferred← citeshttps://doi.org/10.1038/s41573-021-00259-5openalex-snapshot

Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

inferred← citeshttps://doi.org/10.1038/s41576-023-00623-8openalex-snapshot

Steering and controlling evolution — from bioengineering to fighting pathogens

inferred← citeshttps://doi.org/10.1038/s41584-025-01296-9openalex-snapshot

PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease

inferred← citeshttps://doi.org/10.1038/s41590-022-01140-2openalex-snapshot

Catch and release: freeing up PD-L1 ameliorates autoimmunity

inferred← citeshttps://doi.org/10.1038/s41590-022-01210-5openalex-snapshot

Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3

inferred← citeshttps://doi.org/10.1038/s41590-023-01645-4openalex-snapshot

Targeting PGLYRP1 promotes antitumor immunity while inhibiting autoimmune neuroinflammation

inferred← citeshttps://doi.org/10.1038/s41598-025-30220-0openalex-snapshot

Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic

inferred← citeshttps://doi.org/10.1038/s43018-022-00422-wopenalex-snapshot

Checking ovarian reserves after checkpoint blockade

inferred← citeshttps://doi.org/10.1038/s44161-025-00640-2openalex-snapshot

Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis

inferred← citeshttps://doi.org/10.1039/c9nr08086dopenalex-snapshot

Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy

inferred← citeshttps://doi.org/10.1039/d3ma00820gopenalex-snapshot

Melanoma immunotherapy enabled by M2 macrophage targeted immunomodulatory cowpea mosaic virus

inferred← citeshttps://doi.org/10.1053/j.gastro.2020.08.063openalex-snapshot

AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review

inferred← citeshttps://doi.org/10.1053/j.gastro.2021.07.007openalex-snapshot

Immune Checkpoint Inhibitor Colitis: Resident Memory Unleashed

inferred← citeshttps://doi.org/10.1080/14737140.2020.1803742openalex-snapshot

Immune-related adverse events: what we’ve learned and where we’re heading

inferred← citeshttps://doi.org/10.1080/14740338.2025.2467814openalex-snapshot

Impact of baseline glucocorticoids (GCs) on cardiotoxic events and myocardial damage related to immune checkpoint inhibitors: a retrospective clinical research

inferred← citeshttps://doi.org/10.1080/1750743x.2025.2516995openalex-snapshot

Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy

inferred← citeshttps://doi.org/10.1080/2162402x.2021.1944553openalex-snapshot

CanImmunother: a manually curated database for identification of cancer immunotherapies associating with biomarkers, targets, and clinical effects

inferred← citeshttps://doi.org/10.1080/21645515.2024.2408852openalex-snapshot

A systematic review of gastritis as an immune-related adverse event in clinical interventions

inferred← citeshttps://doi.org/10.1080/21645515.2024.2424611openalex-snapshot

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024

inferred← citeshttps://doi.org/10.1084/jem.20192179openalex-snapshot

Understanding adverse events of immunotherapy: A mechanistic perspective

inferred← citeshttps://doi.org/10.1084/jem.20221920openalex-snapshot

Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice

inferred← citeshttps://doi.org/10.1093/ibd/izad229openalex-snapshot

Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach

inferred← citeshttps://doi.org/10.1093/immadv/ltac008openalex-snapshot

Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1093/immadv/ltad011openalex-snapshot

Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression

inferred← citeshttps://doi.org/10.1093/oncolo/oyad154openalex-snapshot

Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors

inferred← citeshttps://doi.org/10.1097/bor.0000000000000684openalex-snapshot

The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy

inferred← citeshttps://doi.org/10.1097/cji.0000000000000473openalex-snapshot

Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy

inferred← citeshttps://doi.org/10.1097/hep.0000000000000045openalex-snapshot

Checkpoint inhibitor hepatotoxicity: pathogenesis and management

inferred← citeshttps://doi.org/10.1097/mog.0000000000000986openalex-snapshot

The colitis may be microscopic, but the diarrhea is not: update on the treatment of microscopic colitis and immune checkpoint inhibitor colitis

inferred← citeshttps://doi.org/10.1097/pas.0000000000001730openalex-snapshot

Histopathology of Gastrointestinal Immune-related Adverse Events: A Practical Review for the Practicing Pathologist.

inferred← citeshttps://doi.org/10.1101/2021.06.10.447979openalex-snapshot

PD-1 checkpoint blockade disrupts CD4 T cell regulated adaptive B cell tolerance to foreign antigens

inferred← citeshttps://doi.org/10.1101/2022.06.05.494592openalex-snapshot

Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment

inferred← citeshttps://doi.org/10.1101/2023.06.17.545426openalex-snapshot

Non-coding sequence variation reveals fragility within interleukin 2 feedback circuitry and shapes autoimmune disease risk

inferred← citeshttps://doi.org/10.1101/2024.12.05.626996openalex-snapshot

Engineering an Anthrax Toxin inspired protein-ligand for Nanoparticle-Mediated Treatment of Malignant Melanoma

inferred← citeshttps://doi.org/10.1101/2024.12.06.626481openalex-snapshot

Potent antitumor activity of a designed interleukin-21 mimic

inferred← citeshttps://doi.org/10.1101/2025.09.03.673981openalex-snapshot

Anti-PD-1/PD-L1 Therapy Triggers Cognitive Deficits and Anxiety-Like Behaviors Through Tumor-Initiated Neuroinflammatory Niches in Male Mice

inferred← citeshttps://doi.org/10.1111/anae.16522openalex-snapshot

Systemic anti‐cancer therapy and anaesthesia: a narrative review

inferred← citeshttps://doi.org/10.1111/ans.18485openalex-snapshot

Immune mediated colitis: a surgical perspective

inferred← citeshttps://doi.org/10.1111/his.13963openalex-snapshot

Immune‐related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies

inferred← citeshttps://doi.org/10.1111/imm.13388openalex-snapshot

PD‐1‐induced proliferating T cells exhibit a distinct transcriptional signature

inferred← citeshttps://doi.org/10.1111/imr.13071openalex-snapshot

Activation pathways that drive CD4 + T cells to break tolerance in autoimmune diseases*

inferred← citeshttps://doi.org/10.1111/imr.13239openalex-snapshot

Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions

inferred← citeshttps://doi.org/10.1126/sciadv.adw1924openalex-snapshot

PET-based immunomapping of intratumoral CD4 + cells to monitor acquired resistance to checkpoint inhibitors

inferred← citeshttps://doi.org/10.1126/sciimmunol.abi7083openalex-snapshot

Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy

inferred← citeshttps://doi.org/10.1126/sciimmunol.adx1582openalex-snapshot

Design of a potent interleukin-21 mimic for cancer immunotherapy

inferred← citeshttps://doi.org/10.1126/scitranslmed.aba6006openalex-snapshot

Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice

inferred← citeshttps://doi.org/10.1136/jclinpath-2020-206540openalex-snapshot

Nivolumab-associated active neutrophilic gastritis

inferred← citeshttps://doi.org/10.1136/jcp-2024-209621openalex-snapshot

Immune checkpoint inhibitor-induced gastrointestinal injury: prevalence of cytomegalovirus, adenovirus and Epstein-Barr virus

inferred← citeshttps://doi.org/10.1136/jitc-2019-000380openalex-snapshot

A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab

inferred← citeshttps://doi.org/10.1136/jitc-2019-000421openalex-snapshot

Neoantigen-specific CD4 + T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy

inferred← citeshttps://doi.org/10.1136/jitc-2019-000451openalex-snapshot

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

inferred← citeshttps://doi.org/10.1136/jitc-2020-000958openalex-snapshot

Immune checkpoint inhibitor-associated celiac disease

inferred← citeshttps://doi.org/10.1136/jitc-2020-001687openalex-snapshot

Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy

inferred← citeshttps://doi.org/10.1136/jitc-2022-005635openalex-snapshot

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

inferred← citeshttps://doi.org/10.1136/jitc-2022-005970openalex-snapshot

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis

inferred← citeshttps://doi.org/10.1136/jitc-2023-007195openalex-snapshot

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis

inferred← citeshttps://doi.org/10.1136/jitc-2023-007555openalex-snapshot

Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research

inferred← citeshttps://doi.org/10.1136/jitc-2024-009051openalex-snapshot

Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors

inferred← citeshttps://doi.org/10.1136/jitc-2024-009345openalex-snapshot

Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

inferred← citeshttps://doi.org/10.1136/jitc-2024-009742openalex-snapshot

Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events

inferred← citeshttps://doi.org/10.1136/jitc-2026-015632openalex-snapshot

Comprehensive characterization of the inflammatory ecosystems in immunotherapy-induced adverse events versus chronic inflammatory diseases

inferred← citeshttps://doi.org/10.1142/s0218127421500887openalex-snapshot

Stochastic Simulation on a Minimal Model of Cancer Immunoediting Theory

inferred← citeshttps://doi.org/10.1146/annurev-immunol-090222-110914openalex-snapshot

T Cell Exhaustion

inferred← citeshttps://doi.org/10.1158/0008-5472.can-20-0435openalex-snapshot

Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis

inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530544openalex-snapshot

Data from Non-invasive Detection of Immunotherapy-Induced Adverse Events

inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530544.v1openalex-snapshot

Data from Non-invasive Detection of Immunotherapy-Induced Adverse Events

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-4641openalex-snapshot

Non-invasive Detection of Immunotherapy-Induced Adverse Events

inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-23-0006openalex-snapshot

Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas

inferred← citeshttps://doi.org/10.1159/000530832openalex-snapshot

The Role of Abdominal Surgery in Refractory Immune Checkpoint Inhibitor Enterocolitis: A Case Report

inferred← citeshttps://doi.org/10.1159/000549888openalex-snapshot

Diagnostic Performance of Fecal Biomarkers and Their Correlation with Endoscopic Severity in Immune Checkpoint Inhibitor-Related Colitis

inferred← citeshttps://doi.org/10.11648/j.ijg.20240801.13openalex-snapshot

A Case of Pemrolizumab-Associated Severe Gastritis Treated with Mycophenolate Mofetil

inferred← citeshttps://doi.org/10.1177/10732748221079474openalex-snapshot

Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis

inferred← citeshttps://doi.org/10.1177/11795514261466123openalex-snapshot

Secondary Adrenocortical Insufficiency in Liver Cancer Patient After Treatment With Cadonilimab: A Case Report

inferred← citeshttps://doi.org/10.1177/15330338261449946openalex-snapshot

Prognostic Impact of Blood Transfusions During Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.1177/22143602261486591openalex-snapshot

Pembrolizumab-associated myasthenia gravis in thymic tumors: A single-center case series and comparative analysis

inferred← citeshttps://doi.org/10.1177/26330040231190661openalex-snapshot

A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report

inferred← citeshttps://doi.org/10.1186/s12885-025-14171-3openalex-snapshot

The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database

inferred← citeshttps://doi.org/10.1186/s12885-025-14712-wopenalex-snapshot

The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis

inferred← citeshttps://doi.org/10.1186/s12943-025-02413-8openalex-snapshot

Neurotransmitters: an emerging target for therapeutic resistance to tumor immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1186/s13019-025-03513-8openalex-snapshot

The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report

inferred← citeshttps://doi.org/10.1186/s13046-022-02264-xopenalex-snapshot

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

inferred← citeshttps://doi.org/10.1186/s13075-025-03546-3openalex-snapshot

Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis

inferred← citeshttps://doi.org/10.1186/s13287-025-04227-3openalex-snapshot

Exosomal miR-125b-5p derived from mesenchymal stromal/stem cell enhances anti-PD-1 therapy in mouse colon cancer model

inferred← citeshttps://doi.org/10.1186/s40364-022-00412-1openalex-snapshot

Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

inferred← citeshttps://doi.org/10.1186/s40425-019-0711-0openalex-snapshot

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

inferred← citeshttps://doi.org/10.1186/s40425-019-0756-0openalex-snapshot

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors

inferred← citeshttps://doi.org/10.1186/s40425-019-0779-6openalex-snapshot

Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1186/s43046-026-00387-2openalex-snapshot

Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis

inferred← citeshttps://doi.org/10.1200/edbk-25-481556openalex-snapshot

One Step Ahead: Preventing Tumor Adaptation to Immune Therapy

inferred← citeshttps://doi.org/10.1245/s10434-019-08183-0openalex-snapshot

Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon

inferred← citeshttps://doi.org/10.1245/s10434-024-16811-7openalex-snapshot

Association Between Treatment-Related Adverse Event Trajectory and Prognosis in Esophageal Cancer Receiving Neoadjuvant Immunochemotherapy

inferred← citeshttps://doi.org/10.1371/journal.pone.0271506openalex-snapshot

Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review

inferred← citeshttps://doi.org/10.1371/journal.pone.0274494openalex-snapshot

Transcriptome analysis of Homo sapiens and Mus musculus reveals mechanisms of CD8+ T cell exhaustion caused by different factors

inferred← citeshttps://doi.org/10.14309/crj.0000000000001252openalex-snapshot

Severe Dysphagia With Eosinophilic Esophagitis Pattern of Injury Related to Pembrolizumab Therapy

inferred← citeshttps://doi.org/10.14309/ctg.0000000000000746openalex-snapshot

The Development of Persistent Gastrointestinal Symptoms in Patients With Melanoma Who Have Had an Immune Checkpoint Inhibitor-Related Gastrointestinal Toxicity

inferred← citeshttps://doi.org/10.1631/jzus.b2300492openalex-snapshot

Immune checkpoint blockade for cancer therapy: current progress and perspectives

showing the first 200 of 276 · page through all 276

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.